EL7.AI
StocksMedium•11 November 2026•
4 min read

Hansa Biopharma’s Third-Quarter Revenue Reaches SEK 143.0 Million, Supported by Serb Agreement

Key Facts

1Third-quarter revenue was SEK 143.0 million, compared with SEK 30.8 million a year earlier, supported by Serb licensing revenue.
2Revenue for the first nine months reached SEK 225.7 million, compared with SEK 146.3 million in the year-earlier period.
3Cash and cash equivalents were SEK 1,337.2 million on September 30, 2026, compared with SEK 252.1 million a year earlier.
4The company reported an operating loss of SEK 138.6 million and a net loss of SEK 178.5 million in the third quarter.
5One-year graft failure-free survival was 90% in the European Idefirix study.

Hansa Biopharma reported revenue of SEK 143.0 million in the third quarter of 2026, compared with SEK 30.8 million in the year-earlier period, driven mainly by revenue from its licensing agreement with Serb Pharmaceuticals. The company said in its financial report that the agreement changed the revenue mix during the quarter. Revenue for the first nine months reached SEK 225.7 million, compared with SEK 146.3 million in the same period of 2025. The company said revenue in the current periods is no longer directly comparable with the year-earlier periods following the licensing of Idefirix to Serb. The agreement gives Serb exclusive marketing rights for the drug in Europe and the Middle East and North Africa for use in organ transplantation.

The quarterly figures separate licensing-related revenue from other commercial revenue: the company recorded SEK 121.6 million in licensing revenue related to Serb’s upfront payment and SEK 20.8 million from supplies and services to the company. It recorded no product sales during the quarter. Hansa closed the licensing agreement on July 1, then received a one-time upfront payment of 110 million euros on July 8. The deal’s announced total value was 115 million euros, while the report listed the upfront payment separately from that total. These items show that the quarterly increase was tied mainly to agreement revenue, not product sales.

Cash and cash equivalents rose to SEK 1,337.2 million on September 30, 2026, from SEK 252.1 million on the same date in 2025. Management attributed the stronger financial position to the Serb deal, and the CEO said its completion strengthened the financial position and defined the company’s strategic focus. At the same time, Hansa reported an operating loss of SEK 138.6 million for the quarter, compared with a loss of SEK 147.6 million a year earlier. The net loss widened to SEK 178.5 million from SEK 148.3 million in the third quarter of 2025. Selling, general and administrative expenses were SEK 147.6 million, while research and development expenses were SEK 65.4 million.

At the cash flow level, the company recorded net cash from operating activities of SEK 964.4 million in the third quarter, compared with net cash used in operating activities of SEK 106.9 million in the year-earlier period. The reversal is consistent with receipt of the Serb upfront payment during the quarter, while the company continued to report operating and net losses. Hansa said the deal enabled it to focus on preparing for a potential U.S. launch of imlifidase, subject to approval. The CEO added that the company continues to develop HNSA-5487 for Guillain-Barré syndrome. The company thus links the deal’s resources to its upcoming commercial and research programs.

The quarter saw Hansa begin commercial activity in Australia, after the first commercial patient received Idefirix treatment before undergoing a kidney transplant from a living donor. The company said the case marked the start of its commercial activities there. After the quarter ended, the European Commission approved the transfer of Idefirix’s marketing authorization and orphan-drug designation to Serb. This is part of the transfer of marketing for the drug in Europe and the Middle East and North Africa to its partner under the agreement. Hansa also presented, on October 23, results from the European post-authorization efficacy and safety study of the drug in kidney transplantation during the American Society of Nephrology’s Kidney Week.

The European study results, as reported by the company, showed that one-year graft failure-free survival was 90% among patients who received imlifidase for desensitization. Graft survival was 92%, while patient survival was 98%. Also after the quarter ended, Hansa submitted an investigational new drug application to the U.S. Food and Drug Administration for HNSA-5487 to treat Guillain-Barré syndrome, aiming to begin clinical development. The company said it would review interim financial results and provide a business and pipeline update on a conference call scheduled for November 11, 2026. A U.S. launch of imlifidase remains contingent on approval, the company said.